ProQR Therapeutics N.V. (PRQR) Stock

ProQR Therapeutics N.V. (PRQR) is a Healthcare stock trading at $1.88 (as of 2026-06-18), with a market capitalization of $145.93M and a trailing P/E of -3.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ProQR Therapeutics N.V. is a biopharmaceutical company focused on the discovery and development of RNA-based therapies for genetic disorders. Its main programs include sepofarsen for Leber congenital amaurosis and ultevursen for USH2A-mediated retinitis pigmentosa and Usher syndrome, alongside development of the Axiomer RNA base-editing platform, supported by licensing and research collaborations.

Valuation — source: SEC EDGAR (first-party)
Price	$1.88
Market Cap	$145.93M
P/E Ratio	-3.5
Price / Book	2.96
Price / Sales	9.17
DCF Value (model)	$-7.65
DCF Upside vs Price	-506.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$15.91M
Net Margin	-265.2%
Return on Equity	-85.4%
Debt / Equity	0.09
Current Ratio	3.09
Revenue Growth (YoY)	-15.9%
EPS Growth (YoY)	25.0%

Valuation vs Sector & Industry
Stock P/E	-3.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-116.6%
vs Industry	-120.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	ADAGE CAPITAL PARTNERS GP, L.L.C. ($10.13M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Daniel Anton de Boer
Employees	166
Country	NL
IPO Date	2014-09-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.